Aprea Therapeutics press release (APRE): Q2 GAAP EPS of -$0.07 beats by $0.16. - As of June 30, 2026, the Company reported cash and cash equivalents of $41.2 million, compared to $14.6 million as of December 31, 2025. The Company believes that its cash and cash equivalents
Aprea Therapeutics press release (APRE): Q2 GAAP EPS of -$0.07 beats by $0.16. – As of June 30, 2026, the Company reported cash and cash equivalents of $41.2 million, compared to $14.6 million as of December 31, 2025.
The Company believes that its cash and cash equivalents as
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
